{"id":300634,"date":"2025-11-22T03:31:11","date_gmt":"2025-11-22T03:31:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/300634\/"},"modified":"2025-11-22T03:31:11","modified_gmt":"2025-11-22T03:31:11","slug":"novo-nordisk-will-soon-reveal-whether-its-glp-1-drug-can-slow-alzheimers-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/300634\/","title":{"rendered":"Novo Nordisk Will Soon Reveal Whether Its GLP-1 Drug Can Slow Alzheimer’s – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

Upcoming data from Novo Nordisk A\/S (NYSE:<\/a>NVO<\/a>) early next month could offer the clearest signal yet on whether GLP-1 medicines \u2014 widely used for diabetes and weight loss \u2014 can also slow the progression of Alzheimer’s disease<\/a>.<\/p>\n

If Rybelsus shows close to a 30% reduction in cognitive decline, it would be viewed as a clear success, Reuters highlighted, citing an expert.<\/p>\n

Even modest results could inform future trial designs or potential combination therapies with existing Alzheimer’s drugs<\/a>.<\/p>\n

Novo will present findings on Dec. 3 at the Clinical Trials on Alzheimer’s Disease meeting in San Diego.<\/p>\n

The company is testing its oral diabetes drug Rybelsus, which contains semaglutide, the same active ingredient as Ozempic and Wegovy, in two late-stage studies that Alzheimer’s experts describe as potentially pivotal.<\/p>\n

According to Reuters, the trials, which Novo itself has likened to a “lottery ticket,” are enrolling thousands of people with mild Alzheimer’s to determine whether the medication can reduce cognitive decline by at least 20%.<\/p>\n

Also Read: FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer\u2019s Therapy<\/a><\/p>\n

Reuters reported that positive results would introduce a new, convenient treatment option for a neurodegenerative disease that affects an estimated 50 million people globally.<\/p>\n

Citing experts, the Reuters report added that the success could reshape the treatment landscape.<\/p>\n

Much of the rationale behind the trials came from research involving diabetes patients, who saw reduced dementia risk when treated with GLP-1s<\/a>.<\/p>\n

Novo launched the Alzheimer’s studies in 2021, following animal research and analyses of human data that suggested potential benefits.<\/p>\n

A small study of liraglutide, the company’s older injectable GLP-1, also reported slower loss of brain volume in patients with mild Alzheimer’s<\/a>.<\/p>\n

The biological mechanisms remain unclear. GLP-1s may directly affect the brain, or the benefits could stem from weight loss and reduced inflammation.<\/p>\n

Notably, all GLP-1 drugs are not identical; preclinical studies suggest liraglutide enters the brain more readily than semaglutide, Reuters added.<\/p>\n

Only two Alzheimer’s slowing drugs are currently approved \u2014 Eli Lilly and Co.’s (NYSE:<\/a>LLY<\/a>) Kisunla and Leqembi from Eisai and Biogen Inc (NASDAQ:<\/a>BIIB<\/a>) \u2014 both of which require infusions or injections and carry risks of serious side effects.<\/p>\n

Read Next:<\/p>\n

Photo: Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Upcoming data from Novo Nordisk A\/S (NYSE:NVO) early next month could offer the clearest signal yet on whether…\n","protected":false},"author":2,"featured_media":300635,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,8331,8335,8334,8332,8333,8330,137,500,8329,117655,8337,62109,93212,38221],"class_list":{"0":"post-300634","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-category-biotech","11":"tag-category-general","12":"tag-category-health-care","13":"tag-category-large-cap","14":"tag-category-news","15":"tag-cms-wordpress","16":"tag-health","17":"tag-healthcare","18":"tag-pageisbzpro-bz","19":"tag-symbol-biib","20":"tag-symbol-lly","21":"tag-symbol-nvo","22":"tag-tag-expert-ideas","23":"tag-tag-stories-that-matter"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/300634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=300634"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/300634\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/300635"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=300634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=300634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=300634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}